PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

Lixisenatide

Lixisenatide is a GLP-1 receptor agonist; in the ELIXA trial of 6,068 people with type 2 diabetes and a recent acute coronary event, it neither raised nor lowered major cardiovascular events against placebo over a median 25 months.

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.